

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/379467572>

Unveiling the Role of GATA-1 in Hematopoietic Stem Cell Function in HIV: Therapeutic Implications

Article in *International Journal of Current Research in Medical Sciences* · April 2024

DOI: 10.22192/ijcrms.2024.10.03.003

CITATIONS

0

READS

4

2 authors:



[Emmanuel Ifeanyi Obeagu](#)

Kampala International University (KIU)

1,601 PUBLICATIONS 20,695 CITATIONS

[SEE PROFILE](#)




[Getrude Uzoma Obeagu](#)

Kampala International University (KIU)

515 PUBLICATIONS 9,302 CITATIONS

[SEE PROFILE](#)



Unveiling the Role of GATA-1 in Hematopoietic Stem Cell Function in HIV: Therapeutic Implications

***Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²**

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²School of Nursing Science, Kampala International University, Uganda.

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Hematopoietic stem cell (HSC) dysfunction is a significant contributor to immune impairment in HIV infection. GATA-1, a pivotal transcription factor in hematopoiesis, emerges as a key regulator influencing HSC function and lineage commitment. This review explores the intricate relationship between GATA-1 and HSCs in the context of HIV, shedding light on potential therapeutic implications. We discuss the impact of GATA-1 dysregulation on hematopoietic processes in HIV, highlighting its role in immune cell differentiation and activation. Furthermore, we examine therapeutic strategies targeting GATA-1 to restore normal hematopoiesis and enhance immune reconstitution in HIV-infected individuals. This comprehensive analysis underscores the importance of understanding GATA-1-mediated mechanisms in shaping immune responses during HIV infection and emphasizes the therapeutic potential of targeting GATA-1 for mitigating immune dysfunction and improving patient outcomes.

Keywords: GATA-1, hematopoietic stem cells, HIV, therapy, immune dysfunction, transcription factor

Introduction

Hematopoietic stem cells (HSCs) serve as the foundation for the body's immune system, continually replenishing various blood cell lineages throughout life. However, in the context of human immunodeficiency virus (HIV) infection, this crucial process becomes dysregulated, leading to profound immune dysfunction. Despite the success of antiretroviral therapy (ART) in suppressing viral replication, immune reconstitution deficits persist,

highlighting the need for a deeper understanding of the underlying mechanisms. Recent research has increasingly implicated GATA-1, a master regulator of hematopoiesis, in the modulation of HSC function. GATA-1's multifaceted role in directing lineage commitment and immune cell development positions it as a pivotal player in HIV-associated hematopoietic abnormalities. GATA-1, a member of the GATA family of transcription factors, governs the expression of genes critical for erythroid and megakaryocytic differentiation. Beyond its canonical roles in

hematopoiesis, GATA-1 also exerts regulatory control over immune cell development and function, influencing T cell activation and differentiation. Given its broad impact on hematopoietic processes, alterations in GATA-1 expression or activity have significant implications for immune homeostasis, particularly in the context of chronic viral infections such as HIV. Understanding the interplay between GATA-1 and HSCs in HIV pathogenesis may offer valuable insights into the mechanisms underlying immune dysfunction and potential therapeutic targets.¹⁻²⁹

In HIV infection, dysregulation of HSC function manifests as impaired hematopoiesis, skewed lineage differentiation, and compromised immune responses. Several studies have highlighted the dysregulation of GATA-1 expression and activity in HIV-infected individuals, suggesting its involvement in the pathogenesis of immune dysfunction. Notably, HIV-mediated perturbations in GATA-1 signaling pathways contribute to aberrant immune cell activation and exhaustion, perpetuating viral persistence and immune evasion. Consequently, elucidating the role of GATA-1 in HIV-associated hematopoietic abnormalities holds promise for identifying novel therapeutic strategies aimed at restoring immune function and mitigating disease progression. By modulating GATA-1 activity pharmacologically or genetically, it may be possible to enhance immune reconstitution and mitigate the long-term consequences of HIV infection. However, the complex regulatory network involving GATA-1 and its downstream effectors necessitates further investigation to delineate precise therapeutic strategies and evaluate their efficacy in clinical settings. Thus, understanding the role of GATA-1 in HIV-associated hematopoietic dysfunction represents a crucial step toward developing targeted interventions to improve outcomes for HIV-infected individuals.³⁰⁻⁴⁹

GATA-1: Master Regulator of Hematopoiesis

GATA-1 stands as a preeminent transcription factor orchestrating the intricate symphony of hematopoiesis, the process by which blood cells are generated from hematopoietic stem cells

(HSCs). Belonging to the GATA family of zinc-finger transcription factors, GATA-1 plays a pivotal role in directing the differentiation and maturation of erythroid and megakaryocytic lineages. Its significance is underscored by its conserved expression across species, from nematodes to humans, highlighting its fundamental role in hematopoietic development. GATA-1 exerts its regulatory influence by binding to specific DNA sequences within target genes, thereby modulating their transcriptional activity and driving lineage-specific gene expression programs. During embryonic development, GATA-1 is indispensable for primitive hematopoiesis, facilitating the emergence of erythroid and megakaryocytic progenitors from mesodermal precursors. Its role extends beyond embryogenesis, as GATA-1 continues to regulate hematopoiesis throughout life, maintaining the balance between self-renewal and differentiation within the adult hematopoietic system. Notably, GATA-1 deficiency results in embryonic lethality due to severe defects in erythropoiesis and megakaryopoiesis, emphasizing its non-redundant function in hematopoietic lineage commitment.⁵⁰

At the molecular level, GATA-1 governs gene expression through interactions with cofactors and chromatin-modifying enzymes, thereby shaping the transcriptional landscape of hematopoietic cells. Key target genes regulated by GATA-1 include those encoding globin chains, essential for hemoglobin synthesis in erythrocytes, and platelet-specific factors critical for thrombopoiesis. Additionally, GATA-1 collaborates with other transcription factors, such as SCL/TAL1 and FLI1, to orchestrate lineage-specific gene expression programs, further underscoring its role as a master regulator of hematopoiesis. Beyond its canonical functions in erythroid and megakaryocytic lineages, emerging evidence suggests that GATA-1 exerts pleiotropic effects on immune cell development and function. GATA-1 is implicated in the regulation of T cell differentiation and activation, influencing thymocyte development and peripheral T cell responses. Moreover, GATA-1 modulates the expression of genes involved in innate immune responses, highlighting its broader impact on immune homeostasis.⁵⁰

Implications of GATA-1 Dysregulation in HIV

HIV infection represents a complex interplay between the virus and the host immune system, leading to progressive immune dysfunction. While much attention has been focused on viral replication and immune cell depletion, emerging evidence highlights the role of dysregulated hematopoiesis in HIV pathogenesis. Among the key regulators implicated in this dysregulation is GATA-1, a master transcription factor in hematopoietic development. Dysregulation of GATA-1 expression and activity in the context of HIV infection has profound implications for hematopoietic stem cell (HSC) function and immune cell homeostasis. One of the primary consequences of GATA-1 dysregulation in HIV is the disruption of normal hematopoiesis. HIV-infected individuals often exhibit hematopoietic abnormalities, including decreased production of erythrocytes, platelets, and immune cells. GATA-1's role in directing lineage commitment and differentiation of HSCs suggests that its dysregulation could contribute to these hematopoietic defects observed in HIV. Indeed, studies have demonstrated altered GATA-1 expression patterns in bone marrow and peripheral blood cells of HIV-infected individuals, correlating with impaired hematopoietic function.⁵⁰⁻⁶⁰

Moreover, GATA-1 dysregulation in HIV may skew immune cell differentiation and activation, exacerbating immune dysfunction. GATA-1 has been implicated in the regulation of T cell development and function, influencing the balance between effector and regulatory T cell subsets. Dysregulated GATA-1 activity in HIV-infected individuals may perturb this balance, leading to aberrant T cell responses characterized by decreased proliferation, impaired cytokine production, and compromised antiviral immunity. Additionally, GATA-1 dysregulation could impact other immune cell populations, including B cells and myeloid cells, further exacerbating immune dysfunction in HIV. The dysregulated expression of GATA-1 in HIV may also contribute to persistent immune activation and inflammation, hallmarks of chronic HIV infection. GATA-1 has been implicated in the

regulation of inflammatory responses, influencing the expression of cytokines and chemokines involved in immune cell recruitment and activation. Dysregulated GATA-1 activity may perpetuate a pro-inflammatory environment in HIV-infected individuals, fueling immune activation and tissue damage. This chronic immune activation not only undermines immune function but also contributes to the pathogenesis of HIV-associated comorbidities, including cardiovascular disease, neurocognitive impairment, and accelerated aging.⁶¹⁻⁸³

Therapeutic Opportunities

The intricate involvement of GATA-1 in hematopoietic dysfunction and immune dysregulation during HIV infection unveils promising therapeutic opportunities for addressing immune impairment and enhancing patient outcomes. Strategies aimed at targeting GATA-1 activity and expression hold significant potential in restoring normal hematopoiesis, rebalancing immune cell homeostasis, and mitigating the long-term consequences of HIV infection. One avenue for therapeutic intervention involves the modulation of GATA-1 activity using small molecule inhibitors or activators. High-throughput screening approaches coupled with structure-based drug design may identify compounds capable of selectively targeting GATA-1 function, either by disrupting its DNA-binding activity or modulating its interaction with cofactors. Such pharmacological interventions could restore the balance between self-renewal and differentiation within HSCs, promoting the production of functional immune cells and enhancing immune reconstitution in HIV-infected individuals. In addition to pharmacological approaches, genetic manipulation of GATA-1 expression represents a promising strategy for therapeutic intervention. Gene editing technologies, such as CRISPR-Cas9, enable precise modification of GATA-1 expression levels in HSCs, offering a means to correct dysregulated hematopoiesis in HIV-infected individuals. By restoring physiological GATA-1 levels, gene therapy approaches could alleviate hematopoietic abnormalities, improve immune

cell function, and enhance the efficacy of existing antiretroviral therapies.⁸⁴⁻¹²⁰

Furthermore, combinatorial approaches targeting GATA-1 in conjunction with other therapeutic modalities may yield synergistic benefits in the management of HIV infection. For instance, combining GATA-1-targeted therapies with immune checkpoint inhibitors or cytokine-based immunotherapies could potentiate immune responses and enhance viral control. Similarly, integrating GATA-1 modulation with strategies aimed at reducing chronic immune activation and inflammation may attenuate HIV-associated comorbidities and improve overall patient well-being. Translating these therapeutic opportunities into clinical practice requires rigorous preclinical evaluation and clinical trials to assess safety, efficacy, and long-term outcomes. Preclinical studies utilizing relevant animal models and ex vivo HSC culture systems can provide valuable insights into the therapeutic potential of GATA-1-targeted interventions in HIV. Subsequently, well-designed clinical trials are needed to evaluate the feasibility, tolerability, and efficacy of GATA-1-based therapies in HIV-infected individuals, with a focus on immune reconstitution, viral suppression, and quality of life outcomes.¹²¹⁻¹⁵⁶

Conclusion

The intricate interplay between GATA-1 dysregulation, hematopoietic dysfunction, and immune impairment in HIV infection unveils novel avenues for therapeutic intervention with far-reaching implications. GATA-1, as a master regulator of hematopoiesis, emerges as a central player linking HIV infection to perturbed immune cell development and function. Dysregulated GATA-1 expression and activity contribute to impaired hematopoiesis, skewed immune cell differentiation, persistent immune activation, and chronic inflammation, collectively fueling disease progression and complicating treatment outcomes.

However, the recognition of GATA-1's pivotal role in HIV pathogenesis also presents therapeutic opportunities for restoring immune function and mitigating disease burden. Pharmacological modulation of GATA-1 activity, gene editing

technologies, and combinatorial therapeutic approaches offer promising avenues for correcting hematopoietic abnormalities, rebalancing immune cell homeostasis, and improving patient outcomes. By targeting GATA-1, it may be possible to enhance immune reconstitution, alleviate chronic immune activation, and reduce the incidence of HIV-associated comorbidities, ultimately improving the quality of life for affected individuals.

References

1. Mann Z, Sengar M, Verma YK, Rajalingam R, Raghav PK. Hematopoietic stem cell factors: their functional role in self-renewal and clinical aspects. *Frontiers in Cell and Developmental Biology*. 2022; 10:664261.
2. Sezaki M, Hayashi Y, Wang Y, Johansson A, Umemoto T, Takizawa H. Immunomodulation of hematopoietic stem and progenitor cells in inflammation. *Frontiers in immunology*. 2020; 11:585367.
3. Okeke C, Silas U, Okeke C, Chikwendu C. Current trends on hemopoietic stem cells. *Current Stem Cell Research & Therapy*. 2021;16(2):199-208.
4. Lee J, Yoon SR, Choi I, Jung H. Causes and mechanisms of hematopoietic stem cell aging. *International Journal of Molecular Sciences*. 2019;20(6):1272.
5. Govindarajah V, Reynaud D. Tuning of the hematopoietic stem cell compartment in its inflammatory environment. *Current stem cell reports*. 2018; 4:189-200.
6. Abunimye DA, Okafor IM, Okorowo H, Obeagu EI. The role of GATA family transcriptional factors in haematological malignancies: A review. *Medicine*. 2024;103(12): e37487.
7. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. *Int. J. Curr. Res. Med. Sci*. 2018;4(10):42-8.
8. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. *Int. J. Adv. Res. Biol. Sci*. 2015;2(7):58-62.
9. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. *EC Emergency*

- Medicine and Critical Care. 2020;4(6):154-67.
10. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
 11. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.<https://madonnauniversity.edu.ng/journal/s/index.php/medicine/article/view/91>.
 12. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2.[links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.2196/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf).
 13. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
 14. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
 15. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
 16. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129.[links/645b4bf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.2196/645b4bf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf).
 17. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
 18. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
 19. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
 20. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471.[links/592bb4990f7e9b9979a975cf/DET-ERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.5923/bb4990f7e9b9979a975cf/DET-ERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf).
 21. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
 22. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI: 10.22192/ijarbs.2016.03.10.009
 23. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among

- patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
24. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
 25. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
 26. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130.links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
 27. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_a1.IJCRAR.pdf.
 28. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.links/5aa2bb17a6fdccd544b7526e/Hematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
 29. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
 30. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
 31. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
 32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
 33. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
 34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.

35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137.links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI:DOI: 10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
42. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211.<http://research.sdpublishers.net/id/eprint/2819/>.
43. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases.* 2022;10(4):1-7.
44. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International.* 2021;33(57A):360-368.

45. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. *Madonna University Journal of Medicine and Health Sciences*. 2022;2(3):42-57.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
46. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
47. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023;10(8): 564-568
48. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf](https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic).
49. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
50. Lionberger JM, Stirewalt DL. Gene expression changes in normal haematopoietic cells. *Best Practice & Research Clinical Haematology*. 2009;22(2):249-269.
51. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-8. DOI: 10.22192/ijcrps.2019.06.12.004 [links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic).
52. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13. DOI: 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic).
53. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assesment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic).
54. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci*. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
55. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med*. 2016;1(2):1-5.
56. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic>

- %20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
57. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
 58. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharma Research.* 2014; 391:186-189.
 59. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
 60. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
 61. Alvarez F, Fritz JH, Piccirillo CA. Pleiotropic effects of IL-33 on CD4+ T cell differentiation and effector functions. *Frontiers in immunology.* 2019; 10:438556.
 62. Chirumbolo S, Bjørklund G, Sboarina A, Vella A. The role of basophils as innate immune regulatory cells in allergy and immunotherapy. *Human vaccines & immunotherapeutics.* 2018;14(4):815-831.
 63. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
 64. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
 65. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
 66. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood TransfusDisord.* 2018;1(2).
 67. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
 68. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
 69. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
 70. Anyiam AF, Arinze-Anyiam OC, Ironde EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
 71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.

72. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
73. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
74. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
75. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
76. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health.* 2024;2(1):8-22.
77. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology.* 2024;2(1):14-33.
78. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine.* 2024;103(9): e37354.
79. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology.* 2024;2(1):1-3.
80. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology.* 2024;2(1):34-46.
81. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):46-58.
82. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine.* 2024;2(1):35-46.
83. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: [http://www.journalijar.com](http://www.journalijar.com;);*12(01).
84. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV.* 2024;2(1):65-78.
85. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: [http://www.journalijar.com](http://www.journalijar.com;);*12(01).
86. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV.* 2024;2(1):31-50.
87. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV.* 2024;2(1):1-5.
88. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
89. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences.* 2024;4(1):32-7.
90. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences.* 2024;4(1):38-44.
91. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science.* 2024;2(1):33-42.
92. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology.* 2024;2(1):26-41.
93. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine.* 2024;2(2):104-15.

94. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
95. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
96. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
97. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
98. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
99. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page: [http://www.journalijar.com](http://www.journalijar.com;);12(01)*.
100. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
101. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
102. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
103. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
104. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
105. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
106. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.
107. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
108. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
109. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
110. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
111. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
112. Obeagu EI, Amaeze AA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
113. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):11-24.
114. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.

115. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.
116. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
117. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: <http://www.journalijar.com>*;12(01).
118. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>*;12(01).
119. Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in Confronting HIV Stigma. *Elite Journal of Public Health*. 2024;2(3):22-36.
120. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
121. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
122. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.
123. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
124. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
125. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):41-51.
126. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
127. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.
128. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
129. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
130. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
131. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
132. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
133. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.
134. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
135. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
136. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.

137. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):9-19.
138. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review.* 2024;2(1):42-60.
139. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine.* 2024;2(2):104-5.
140. Obeagu EI, Obeagu GU, Odo EO, Igwe MC, Ugwu OP, Alum EU, Racheal P. Combatting Stigma: Essential Steps in Halting HIV Spread. *IAA Journal of Applied Sciences.* 2024;11(1):22-9.
141. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology,* 2024; 2 (3):25-41.
142. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science.* 2024;2(1):33-42.
143. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV.* 2024;2(2):43-59.
144. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science.* 2024;2(3):23-35.
145. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science.* 2024;2(1):21-31.
146. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science.* 2024;2(3):84-99.
147. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science.* 2024;2(2):20-35.
148. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine.* 2024;2(2):30-46.
149. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):30-40.
150. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health.* 2024;2(1):35-51.
151. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine.* 2024;2(3):48-59.
152. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology.* 2024;2(2):43-59.
153. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):14-32.
154. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review.* 2024;2(1):17-41.
155. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine.* 2024;2(1):1-6.

156. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2 (3):111-7.

Access this Article in Online	
	Website: www.ijcrims.com
	Subject: Medical Sciences
Quick Response Code	

[How to cite this article:](#)

Emmanuel Ifeanyi Obeagu and Getrude Uzoma Obeagu. (2024). Unveiling the Role of GATA-1 in Hematopoietic Stem Cell Function in HIV: Therapeutic Implications. Int. J. Curr. Res. Med. Sci. 10(3): 10-23.

DOI: <http://dx.doi.org/10.22192/ijcrms.2024.10.03.003>